NVCR · US market

NOVOCURE LTD COMMON STOCK

Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.

Market cap US$1.85bnFinancials dated 30 June 2026Price dated 1 October 2026

Core valuation

Trailing P/E-12.48×

Latest-quarter run-rate P/E-29.60×

Trailing P/S2.65×

Latest-quarter run-rate P/S2.52×

Calculation inputs

Trailing earnings: -US$148.57m
Latest-quarter run-rate earnings: -US$62.63m
Latest fiscal-year earnings: -US$136.23m
Trailing revenue: US$699.19m
Latest-quarter run-rate revenue: US$734.34m
Latest fiscal-year revenue: US$655.35m

Featured ETF and mutual-fund exposure

These public funds report this company in their latest disclosed holdings.

XHE · State Street SPDR S&P Health Care Equipment ETF1.58% weight · Holdings dated 19 August 2026
HEAL · Global X HealthTech ETF1.32% weight · Holdings dated 31 May 2026
PTH · Invesco Dorsey Wright Healthcare Momentum ETF0.68% weight · Holdings dated 19 August 2026
QQQS · Invesco NASDAQ Future Gen 200 ETF0.51% weight · Holdings dated 31 May 2026
AGNG · Global X Aging Population ETF0.48% weight · Holdings dated 31 May 2026
ISRA · VanEck Israel ETF0.48% weight · Holdings dated 30 June 2026
ORSIX · North Square Dynamic Small Cap Fund Class I0.36% weight · Holdings dated 31 May 2026
TMED · T. Rowe Price Health Care ETF0.31% weight · Holdings dated 30 June 2026
IHI · iShares U.S. Medical Devices ETF0.26% weight · Holdings dated 19 August 2026
ASQAX · American Century Small Company Fund A Class0.21% weight · Holdings dated 30 June 2026

Sources and limitations

Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.

Open financial source

Financials as of 30 June 2026. Informational research, not investment advice.